Patients with gastrointestinal bleeding or any other hemorrhage/bleeding event Common Terminology Criteria for Adverse Events (CTCAE) grade >= 3 within 30 days prior to study entry
Has known gastrointestinal bleeding or any other hemorrhage/bleeding event Common Terminology Criteria for Adverse Events (CTCAE) grade > 3 within 6 months of start of study drug
Any hemorrhage or bleeding event >= National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) grade 3 within 4 weeks prior to start of study medication
Has gastrointestinal bleeding or any other hemorrhage/bleeding event Common Terminology Criteria for Adverse Events (CTCAE) grade > 3 within 6 months of registration
Contraindication to antiangiogenic agents, including:\r\n* Serious non-healing wound, non-healing ulcer, or bone fracture\r\n* Major surgical procedure or significant traumatic injury within 4 weeks prior to initiating study treatment\r\n* Pulmonary hemorrhage/bleeding event >= grade 2 (Common Terminology Criteria for Adverse Events [CTCAE] v4.0) within 12 weeks prior to initiating study treatment\r\n* Any other hemorrhage/bleeding event >= grade 3 (CTCAE v4.0) within 12 weeks prior to initiating study treatment
Pulmonary hemorrhage/bleeding event > Common Terminology Criteria for Adverse Events (CTCAE) grade 2 within 4 weeks of first dose of study drug
Contraindication to antiangiogenic agents, including:\r\n* Bronchopulmonary hemorrhage/bleeding event >= grade 2 (Common Terminology Criteria for Adverse Events [CTCAE] v4.0) within 12 weeks prior to of initiation of treatment\r\n* Any other hemorrhage/bleeding event >= grade 3 (CTCAE v4.0) within 12 weeks prior to initiation of treatment\r\n* Serious non-healing wound, ulcer, or bone fracture
Patients with gastrointestinal bleeding or any other hemorrhage/bleeding event (Common Terminology Criteria for Adverse Events [CTCAE] version [v.]4) grade 3 or greater within 30 days prior to registration will be ineligible
Contraindication to antiangiogenic agents, including:\r\n* Bronchopulmonary hemorrhage/bleeding event >= grade 2 (National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] version 4.0) within 4 weeks or less prior to first dose of study drug\r\n* Any other hemorrhage/bleeding event >= grade 3 (CTCAE version [v]4.0) within 4 weeks or less prior to first dose of study treatment\r\n* Radiological evidence of any intracranial hemorrhage within the 4 weeks or less prior to first dose of study treatment \r\n* History of significant intratumoral, intracerebral, or subarachnoid hemorrhage\r\n* Serious non-healing wound, ulcer, or bone fracture\r\n* Documented bowel perforation within 6 months of the start of study treatment
Pulmonary hemorrhage/bleeding event >= Common Terminology Criteria for Adverse Events (CTCAE) grade 2 within 4 weeks of first dose of study drug
Subjects who have a history or current evidence of bleeding disorder, i.e. any hemorrhage/bleeding event of Common Terminology Criteria for Adverse Events (CTCAE) grade >= 2 within 4 weeks before the start of study treatment
Has history of gastrointestinal bleeding or any other hemorrhage/bleeding event >= grade 3 (Common Terminology Criteria for Adverse Events [CTCAE], version [v.] 4) within 30 days prior to entry in to the trial
Subjects who have a history or current evidence of bleeding disorder, i.e. any hemorrhage / bleeding event of CTCAE (Common Terminology Criteria for Adverse Events) Grade ?2 within 4 weeks before the start of study Treatment.
Has gastrointestinal bleeding or any other hemorrhage/bleeding event Common Terminology Criteria for Adverse Events (CTCAE) grade > 3 within 6 months of start of study drug
Any hemorrhage or bleeding event >= National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4 grade 3 =< 4 weeks prior to registration
Gastrointestinal bleeding or any other hemorrhage/bleeding event Common Terminology Criteria for adverse Events (CTCAE), v. 4 grade 3 or greater within 30 days prior to registration
Patients with evidence or history of bleeding diathesis. Any hemorrhage or bleeding event ? CTCAE Grade 3 within 4 weeks of start of study medication (CTCAE: Common Terminology Criteria for Adverse Events).
Patients with gastrointestinal bleeding or any other hemorrhage/bleeding event Common Terminology Criteria for Adverse Events (CTCAE) grade >= 3 within 30 days prior to study entry
Evidence or history of bleeding diathesis. Any hemorrhage/bleeding event ? CTCAE (Common terminology criteria for adverse events) Grade 3 within 4 weeks of first dose of study drug
Any hemorrhage or bleeding event >= National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version (v)4.0 grade 3 within 4 weeks prior to start of study medication
Has gastrointestinal bleeding or any other hemorrhage/bleeding event National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) >Grade 3 within 6 months of start of study drug.
Pulmonary hemorrhage/bleeding event > National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE, version 4.0) grade 2 within 4 weeks of enrollment
Pulmonary hemorrhage/bleeding event >= Common Terminology Criteria for Adverse Events (CTCAE) grade 2 within 4 weeks of first dose of study drug
Pulmonary hemorrhage/bleeding event >= Common Terminology Criteria for Adverse Events (CTCAE) Grade 2 within 4 weeks of first dose of study drug
Any hemorrhage or bleeding event >= Common Terminology Criteria for Adverse Events (CTCAE) grade 3 within 4 weeks prior to start of study medication